Filter By:

Journal Check one or more journals to show results from those journals only.

Choose more journals

Article type Check one or more article types to show results from those article types only.
Subject Check one or more subjects to show results from those subjects only.
Date Choose a date option to show results from those dates only.

Custom date range

Clear all filters
Sort by:
Showing 1–8 of 8 results
Advanced filters: Author: Orhan Aktas Clear advanced filters
  • Only moderately effective therapies are currently available for the treatment of multiple sclerosis (MS). New treatments for MS that have neuroprotective properties as well as anti-inflammatory effects are needed. Fingolimod could be one such potential treatment. In this article, Aktas et al. examine the underlying biological actions of this prospective new therapy, review the data from phase II and phase III oral fingolimod clinical trials and provide an update on the emerging field of sphingosine-1-phosphate receptor-mediated therapies for MS.

    • Orhan Aktas
    • Patrick Küry
    • Hans-Peter Hartung
    Reviews
    Nature Reviews Neurology
    Volume: 6, P: 373-382
  • Modulating the entry of inflammatory T cells into the brain could be one way to treat the autoimmune disease multiple sclerosis. Now, Frauke Zipp and colleagues demonstrate that activation of kinin receptor B1 can block autoimmune T cell migration into the brain and can therefore inhibit experimental autoimmune encephalomyelitis in mice.

    • Ulf Schulze-Topphoff
    • Alexandre Prat
    • Frauke Zipp
    Research
    Nature Medicine
    Volume: 15, P: 788-793
  • The prognostic value of OCT in progressive vs relapsing multiple sclerosis (MS) is not clear. Analyzing 2651 OCTs of 407 MS patients, OCT predicted activity in all MS subtypes cross sectionally but longitudinal changes were not predictive in a multicenter setting.

    • Julia Krämer
    • Carolin Balloff
    • Philipp Albrecht
    ResearchOpen Access
    Nature Communications
    Volume: 15, P: 1-16
  • Susac syndrome is an important differential diagnosis in many neurological disorders, but our understanding of this rare disease has largely been limited to reports of single cases and small case series. In this article, Dörr and colleagues review all reported cases of Susac syndrome to provide a comprehensive overview of demographic, clinical and diagnostic data on this disorder. On the basis of their findings, Dörr et al. make recommendations for diagnosis and management of individuals with suspected Susac syndrome.

    • Jan Dörr
    • Sarah Krautwald
    • Ilka Kleffner
    Reviews
    Nature Reviews Neurology
    Volume: 9, P: 307-316
  • The importance of reported neurological manifestations of coronavirus disease 2019 (COVID-19) is still unclear. Nevertheless, an immediate and ongoing neurological challenge posed by the COVID-19 pandemic is the management of patients who are undergoing immunotherapy for existing neuroimmunological disease.

    • Hans-Peter Hartung
    • Orhan Aktas
    Comments & Opinion
    Nature Reviews Neurology
    Volume: 16, P: 347-348
  • Multiple sclerosis (MS) is an immune-mediated neurological disorder featuring central nervous system demyelination. Increasing understanding of the complex pathophysiology of this disease has led to considerable expansion of the MS therapeutic toolbox over the past 20 years, but substantial limitations remain. In this Review, Sven Meuth and colleagues highlight promising non-classical targets for MS that could provide fruitful avenues for future therapies.

    • Laura Bierhansl
    • Hans-Peter Hartung
    • Sven G. Meuth
    Reviews
    Nature Reviews Drug Discovery
    Volume: 21, P: 578-600